JP7807756B2 - 所望の特異性を有するエフェクター細胞の製造方法 - Google Patents

所望の特異性を有するエフェクター細胞の製造方法

Info

Publication number
JP7807756B2
JP7807756B2 JP2022552076A JP2022552076A JP7807756B2 JP 7807756 B2 JP7807756 B2 JP 7807756B2 JP 2022552076 A JP2022552076 A JP 2022552076A JP 2022552076 A JP2022552076 A JP 2022552076A JP 7807756 B2 JP7807756 B2 JP 7807756B2
Authority
JP
Japan
Prior art keywords
cells
gene
tcr
cell
marker protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022552076A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022065444A5 (https=
JPWO2022065444A1 (https=
Inventor
宏 河本
保年 縣
誠治 永野
晃士 寺田
喬子 増田
健太 近藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiga University of Medical Science NUC
Kyoto University NUC
Original Assignee
Shiga University of Medical Science NUC
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiga University of Medical Science NUC, Kyoto University NUC filed Critical Shiga University of Medical Science NUC
Publication of JPWO2022065444A1 publication Critical patent/JPWO2022065444A1/ja
Publication of JPWO2022065444A5 publication Critical patent/JPWO2022065444A5/ja
Application granted granted Critical
Publication of JP7807756B2 publication Critical patent/JP7807756B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022552076A 2020-09-24 2021-09-24 所望の特異性を有するエフェクター細胞の製造方法 Active JP7807756B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020160252 2020-09-24
JP2020160252 2020-09-24
PCT/JP2021/035150 WO2022065444A1 (ja) 2020-09-24 2021-09-24 所望の特異性を有するエフェクター細胞の製造方法

Publications (3)

Publication Number Publication Date
JPWO2022065444A1 JPWO2022065444A1 (https=) 2022-03-31
JPWO2022065444A5 JPWO2022065444A5 (https=) 2024-12-26
JP7807756B2 true JP7807756B2 (ja) 2026-01-28

Family

ID=80846656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552076A Active JP7807756B2 (ja) 2020-09-24 2021-09-24 所望の特異性を有するエフェクター細胞の製造方法

Country Status (9)

Country Link
US (1) US20230357715A1 (https=)
EP (1) EP4219707A4 (https=)
JP (1) JP7807756B2 (https=)
KR (1) KR20230074505A (https=)
CN (1) CN116406423A (https=)
AU (1) AU2021349574A1 (https=)
CA (1) CA3193384A1 (https=)
IL (1) IL301534A (https=)
WO (1) WO2022065444A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021000459A (es) * 2018-07-13 2021-06-23 Univ Kyoto Metodo para producir celulas t gamma y delta.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105316362A (zh) 2015-08-19 2016-02-10 暨南大学 一种Dual-RMCE介导的TCR基因置换系统及其方法
WO2019232409A1 (en) 2018-05-31 2019-12-05 Washington University Methods for genome editing and activation of cells
WO2020022512A1 (ja) 2018-07-26 2020-01-30 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014248119B2 (en) 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
WO2016010155A1 (ja) 2014-07-18 2016-01-21 宏 河本 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法
EP3170896B1 (en) 2014-07-18 2020-03-11 Kawamoto, Hiroshi Production method for pluripotent stem cells having antigen-specific t cell receptor gene
JPWO2016010153A1 (ja) 2014-07-18 2017-04-27 宏 河本 免疫細胞療法用ｔ細胞の誘導方法
ES2886631T3 (es) 2016-04-15 2021-12-20 Univ Kyoto Método para inducir células T positivas para CD8 específicas de antígeno

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105316362A (zh) 2015-08-19 2016-02-10 暨南大学 一种Dual-RMCE介导的TCR基因置换系统及其方法
WO2019232409A1 (en) 2018-05-31 2019-12-05 Washington University Methods for genome editing and activation of cells
WO2020022512A1 (ja) 2018-07-26 2020-01-30 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cell. 2020 Apr 16;181(3):728-744.e21. doi: 10.1016/j.cell.2020.03.039
J Clin Invest. 2016;126(10):3814-3826. doi:10.1172/JCI87366.
Mol Ther. 2013 Oct 22;21(11):2087-2101. doi: 10.1038/mt.2013.185
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (ACTengine)，2020.01.14更新，ClinicalTrials.gov ID NCT03247309，[検索日 2025.06.27], Internet <URL：https://clinicaltrials.gov/study/NCT03247309?tab=history&a=12#version-content-panel>

Also Published As

Publication number Publication date
EP4219707A1 (en) 2023-08-02
CN116406423A (zh) 2023-07-07
CA3193384A1 (en) 2022-03-31
KR20230074505A (ko) 2023-05-30
US20230357715A1 (en) 2023-11-09
JPWO2022065444A1 (https=) 2022-03-31
WO2022065444A1 (ja) 2022-03-31
AU2021349574A1 (en) 2023-05-11
EP4219707A4 (en) 2024-11-13
IL301534A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
US20260043032A1 (en) Altering gene expression in cart cells and uses thereof
JP7422365B2 (ja) 外来抗原レセプター遺伝子導入細胞の製造方法
KR102761346B1 (ko) 저항원성 세포의 제조 방법
AU2016379393B2 (en) Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
KR102614675B1 (ko) 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
JP6933898B2 (ja) 養子細胞治療製品を製造するための誘導多能性幹細胞の適用
US20190161530A1 (en) Chimeric antigen receptor t cell compositions
US20190241910A1 (en) Genome edited immune effector cells
KR20210075086A (ko) 범용 공여자 세포
KR20170002381A (ko) 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법
KR20210089707A (ko) 항-liv1 면역세포 암 치료법
JP2024534720A (ja) 遺伝子改変細胞を作製するための方法
KR102030364B1 (ko) 멀티플렉스 CRISPR-Cas9 시스템을 이용한 HLA 결핍 세포주로부터 제조된 인공항원제시세포 및 이의 용도
CN116715750B (zh) 特异性识别prame抗原的tcr及其与cd8共表达来重定向cd4 t细胞
JP7807756B2 (ja) 所望の特異性を有するエフェクター細胞の製造方法
WO2021170089A1 (en) Engineering immune cells via simultaneous knock-in and gene disruption
JP2025506976A (ja) 低免疫原性幹細胞、幹細胞から分化または由来した低免疫原性細胞およびこの製造方法
US20210238535A1 (en) Automated production of car-expressing cells
WO2025124489A1 (zh) Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
KR20230122628A (ko) 부위-지향 돌연변이 유발을 위한 조성물 및 방법
JP2024534003A (ja) 細胞ベースの治療法に向けた細胞の操作、ならびに関連する組成物及び方法
CN110484523A (zh) 一种锌指核酸酶及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241218

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260107

R150 Certificate of patent or registration of utility model

Ref document number: 7807756

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150